Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and until six months after completion of study therapy
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
Unwillingness to use an effective contraceptive method for the duration of their study participation and for at least  month after treatment is completed if sexually active with reproductive potential
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for at least  months after treatment is completed
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained; lactating females are not eligible unless they have agreed not to breastfeed their infants for the duration of protocol therapy; sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of protocol therapy
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
Males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
Sexually active patients of reproductive potential who have not agreed to be abstinent or use  forms of effective contraception during treatment through  month off therapy are excluded
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for  days after the last dose of chemotherapy
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
Sexually active patients of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of treatment and for  months after stopping treatment
Pregnancy and breast feeding\r\n* Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential\r\n* Lactating females who plan to breastfeed their infants\r\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
This criteria apply ONLY to patients who will receive chemotherapy (all groups other than Group E): \r\n* Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential\r\n* Lactating females who plan to breastfeed their infants\r\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation\r\n** Note for Group F: patients of childbearing potential should use effective birth control during treatment with sorafenib and for at least  weeks after stopping treatment
Patients must not be pregnant or nursing; women and men of reproductive potential must have agreed to use an effective contraceptive method
Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive methods as follows: fertile females of childbearing potential who agree to use adequate contraceptive measures from  weeks prior to the study and until  month after study treatment discontinuation; male patients willing to abstain or use barrier contraception (i.e. condoms) for the duration of the study and for  months after treatment stops
Patients must not be pregnant or nursing because of the potentially harmful effects of these agents on a developing fetus; women/men of reproductive potential must have agreed to use an effective contraceptive method
Pregnant or nursing patients due to risk of fetal or nursing infant harm. Women/men of reproductive potential who do not agree to use an effective contraceptive method while on study and for at least  months after study treatment
Pregnant or breast-feeding patients; men and women of reproductive potential may not participate in this study unless they have agreed to use an effective contraceptive method while in this study
Men and women of reproductive potential may not participate unless they agree to use an effective contraceptive method
Males who have partners of reproductive potential must agree to use an effective barrier contraceptive method for  days after the last dose of study therapy (durvalumab or JCAR)
Pregnant or nursing women may not participate; women of childbearing potential may not participate unless they have agreed to use an adequate contraceptive method throughout study treatment and for one month after completion of treatment
Men of reproductive potential may not participate unless they agree that they will use an effective contraceptive method such as condom/diaphragm, spermicidal foam, etc - until six months after the end of all radiation therapy
Pregnant or breast-feeding patients; men and women of reproductive potential may not participate in this study unless they have agreed to use an effective contraceptive method while in this study; (postmenopausal woman must have been amenorrheic for at least  months to be considered of non-childbearing potential); patients must agree to continue contraception for  months from the date of the last study drug administration
Women/men of reproductive potential unwilling or unable to use an effective contraceptive method
Pregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for  months after the trial
Patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for  months after the trial; patients must not be breastfeeding
Patients must not be pregnant or nursing. Women/men of reproductive potential must have agreed to use an effective contraceptive method (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
Pregnant or nursing women are ineligible and patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial
Non-pregnant and non-nursing; men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on the study
Women/men of childbearing potential must have agreed to use a highly effective contraceptive method during and for  months after completion of chemotherapy.
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for  months after the last dose of veliparib
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation; women of childbearing potential must have a negative pregnancy test done within  days prior to registration
Pregnancy or breast-feeding: Female patients who are pregnant are ineligible for study; lactating females are not eligible unless they have agreed not to breastfeed their infants from the time of informed consent through the duration and at least  month following the study; female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained; sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method from the time of informed consent through the duration and for  month following study participation; the definition of an effective contraceptive method will be at the discretion of the institutional investigator
Patients with reproductive potential declining to use an effective contraceptive method during treatment are excluded from this study.
Pregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Male and female participants of reproductive potential must use an effective contraceptive method during the study and for a minimum of  months after study treatment
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation; patients should maintain adequate contraception for a minimum of  months after the last dose of ch. (dinutuximab)
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for  months after the last dose of chemotherapy
Reproductive potential must be either terminated (by surgery, radiation, or menopause) or attenuated by the use of an approved contraceptive method during and for  to  months following the study
Pregnant or lactating women; patients in reproductive age must agree to use contraceptive methods for the duration of the study (a pregnancy test will be obtained before treatment)
Patients with reproductive potential must use an effective method to avoid pregnancy for the duration of the trial
Patients at reproductive potential must agree to practice an effective contraceptive method. Women of childbearing potential must not be pregnant or lactating
Patients who are pregnant or nursing; if patients are of reproductive age and have not undergone hysterectomy, they must use an effective contraceptive method for the duration of this study
Women of reproductive potential must have a negative pregnancy test within  days prior to registration; patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method
For B-LLy patients the following additional exclusion criteria apply:\r\n* T-lymphoblastic lymphoma\r\n* Morphologically unclassifiable lymphoma\r\n* Absence of both B-cell and T-cell phenotype markers in a case submitted as lymphoblastic lymphoma\r\n* CNS-positive disease or testicular involvement\r\n* M (% - % blasts) or M (> % blasts) marrow\r\n* Female patients who are pregnant are ineligible\r\n* Lactating females are not eligible unless they have agreed not to breastfeed their infants\r\n* Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\r\n* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
Males and females of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method
Females of reproductive potential must not be pregnant or lactating; males or females of  reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method
Pregnancy and breast feeding\r\n* Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential\r\n* Lactating females who plan to breastfeed their infants while on study therapy and through  months after completion of study therapy\r\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for  months after the end of study treatment
Patient at reproductive potential must agree to practice an effective contraceptive method.
Female or male participant of reproductive potential must agree to use an effective contraceptive method throughout duration of study treatment
Male and female patients of reproductive potential must use an effective contraceptive method during the study and for a minimum of  year after the after study treatment
Women of reproductive potential must have a negative blood pregnancy test and agree to use highly effective contraceptive methods.
Pregnant or nursing women may not participate; women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; pregnancy test required for women of childbearing potential
Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method from the time of study entry to a period of no less than four months post the HSV injection
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for  months after the end of study treatment
Pregnant or nursing females; any patient of reproductive potential may not participate unless he/she has agreed to use an effective contraceptive method as covered during the informed consent process
Patients with reproductive potential must use contraceptive methods
Pregnancy and breast feeding\r\n* Female patients who are pregnant are ineligible\r\n* Lactating females are not eligible unless they have agreed not to breastfeed their infants\r\n* Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\r\n* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
Female patients who are post-menarchal must have a negative pregnancy test; patients of reproductive potential must agree to use an effective contraceptive method
Pregnant or lactating women may not participate; women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
Women who are pregnant or breastfeeding are excluded; patients with reproductive potential must agree to use an effective contraceptive method during treatment
Sexually active female patients of reproductive potential are not eligible unless they agree to use an effective contraceptive method during study and for  months after stopping the study drug; abstinence is an acceptable method of birth control
Female patient who is postmenarcheal has agreed to use an effective contraceptive method (including abstinence) for the duration of study participation
Pregnant or nursing women will not participate; women of reproductive potential must be offered a pre-treatment pregnancy test and informed of the need to practice an effective contraceptive method during the therapy
